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Introduction 
The transjugular intrahepatic portosystemic shunt
(TIPS) is a nonsurgical percutaneous interventional
procedure in which an expandable metal prosthesis is placed
between hepatic vein and intrahepatic portal vein through the
liver parenchyma to enable decompression of portal
hypertension.
Since its introduction into clinical practice, TIPS has
become widely accepted worldwide as an effective procedure
for treating complications of portal hypertension.1 In addition
TIPS is useful for Budd-Chiari syndrome and hepatorenal
syndrome, although it's specific role in these indications
remains to be definitely established. A number of trials
worldwide have compared the safety and efficacy of TIPS
versus medical and endoscopic treatment in management of
above mentioned conditions.1
In Pakistan the incidence of hepatitis and subsequent
cirrhosis is fairly high and management of portal
hypertension and its sequelae poses a problem for clinicians.2
Abbas et al have observed that chronic liver disease is the
commonest cause of ICU admissions and its complications
are the commonest cause of all deaths in ICU.3 Although the
outcome of surgical shunts for the management of portal
hypertension has been studied locally in the past4 but no local
data is available regarding radiological creation of
intrahepatic portosystemic shunt.
In this retrospective study we evaluated the
therapeutic efficacy and safety of TIPS procedure in
treatment of refractory complications of portal hypertension
as well as in managing Budd-Chiari syndrome by use of self-
expanding metallic stents.
Patients and Methods
Retrospective data was reviewed of patients who
underwent TIPS procedure at Radiology department of Aga
Khan University Hospital between January 2001 and May
2008. 
Study sample comprised of 19 patients (10 males and
9 females, age range 25-69 years, mean age 48.31 ± 15.19
years) who were referred to our department for TIPS
placement. Sampling was performed by non probability
purposive technique. Sixteen out of those 19 patients
underwent successful shunt creation while the procedure was
unsuccessful in 3 patients. 
TIPS procedures were performed in the angiography
suite on Siemens angiography machine by trained and
Vol. 61, No. 4, April 2011 336
Original Article
Transjugular Intrahepatic Portosystemic Shunt (TIPS); review of
initial experience at Aga Khan University Hospital
Rana Shoaib Hamid, Tanveer-ul-Haq, Muhammad Azeemuddin, Zafar Sajjad, Ishtiaq Chishti, Basit Salam
Radiology Department, Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objective: To retrospectively assess the therapeutic effectiveness and safety of transjugular intrahepatic
portosystemic shunt (TIPS) in patients with portal hypertension related complications. 
Methods: Over a period of 7.5 years 19 patients (10 males and 9 females, age range 25-69 years) were referred
for TIPS at our radiology department. Thirteen patients suffered from liver cirrhosis while 6 had Budd Chiari
syndrome. All patients were evaluated with colour doppler ultrasonography and cross sectional imaging. Shunt
procedures were performed under sedation or general anaesthesia through internal jugular approach. Metallic
self expandable uncovered stents were placed in 15 patients and covered stent in 1 patient. Follow up of patency
was evaluated with ultrasound in majority and by venography in some patients. Safety of the procedure and
clinical outcome were analyzed.
Results: Indications of procedure included variceal bleeding (n = 8), ascites (n = 4), ascites and bleeding (n=1)
and Budd-Chiari syndrome (n = 6). Technical success rate was 84.21%. Complication rate was 10.53%. Three
days mortality was 15.79 %. Mean primary shunt patency was 306.62 ± 533 days. During follow-up stent
occlusion occurred in 5 patients (31.25%). Four of these patients underwent successful reintervention.
Recurrence of symptoms occurred in 68.75% patients.
Conclusion: TIPS is useful for management of complications of portal hypertension that are refractory to
pharmacological and endoscopic treatment, however shunt stenosis or occlusion may cause recurrence of
symptoms. Repeated interventions are often required to maintain shunt patency. 
Keywords: Interventional procedures, Portal Hypertension, Shunts, TIPS (JPMA 61:336; 2011).
experienced interventional radiologists. Pre procedure
diagnostic work up was done with ultrasound Doppler and
CT scanning. Informed consent was taken prior to the
procedure from the patients or next of kin. All patients
underwent complete blood count and coagulation screening
tests and received broad-spectrum antibiotics. Any existing
coagulopathy was corrected prior to procedure. Procedure
was carried out under monitored anaesthesia care. 
After puncturing the right internal jugular vein under
ultrasound guidance, a 9 or 10 Fr, long sheath (Brite Tip,
Cordis corporation USA) was placed. The right or middle
hepatic vein was cannulated with a 4 -5 Fr angiographic
catheter (RDC, C1. Cordis corporation USA). The right
portal vein was then punctured by passing a long curved 16
gauge Colapinto needle (Cook Medical USA). Portal
puncture was either performed under direct ultrasound
guidance or by opacifying the portal vein via contrast
injection in superior mesenteric artery. An alternative
approach was to identify the right portal vein branch by
ultrasound and putting a radio-opaque metallic marker on
hypochondrium on skin at this level, puncture was then
performed under fluoroscopic guidance. In few patients a
wedged hepatic venogram using water soluble non ionic
contrast was performed. By using this venogram as a guide,
right branch of portal vein was punctured.
The portosystemic pressure gradient was measured
and the intrahepatic parenchymal tract dilated over a 0.035-
inch Amplatz superstiff guide wire (Boston Scientific) with
angioplasty balloon. Metallic self expandable stent
(WALLSTENT {Boston Scientific} or S.M.A.R.T.™ Nitinol
Stent {Cordis Corporation}) was then deployed in the shunt
tract. 10 x 80 mm stents were used in majority of patients.
Postprocedural venography was performed to document
procedure success and to rule out any immediate shunt
thrombosis or stenosis (Figure). Portosystemic gradients
were also measured. Right hepatic vein-portal shunt was
created in 11 patients while left hepatic vein-portal shunt in 2
patients. In 3 patients, cavo portal shunts were created
because hepatic veins could not be catheterized. Selective
embolization of gastro esophageal varices by coils was also
performed in same sitting in seven patients. 
Technical success of shunt placement was defined as
successful creation of shunt with satisfactory position and
regular stent patency resulting in reduction in portosystemic
gradient below 12 mm of Hg. In 3 patients TIPS placement
was unsuccessful due to failure to cannulate hepatic veins
owing to chronic occlusion and extremely hard liver
parenchyma.
Major complications were defined as those requiring
active management. Minor complications were defined as
those which did not required active management and patient
improved after observation.
Patients subsequently underwent ultrasound at 3
months and then every 6 months, or more frequently if
clinically indicated. Whenever shunt occlusion or stenosis
was suspected on basis of clinical assessment or ultrasound
examination, further assessment was performed with
angiography and angioplasty or re- stenting was performed to
establish patency if required.
Results
Out of total 19 patients, 13 had cirrhosis of liver
(68.42%) while 6 patients (31.58%) were diagnosed with
Budd-Chiari Syndrome. Aetiology of cirrhosis and
indications for TIPS are outlined in Table-1.
Technical success in TIPS placement was achieved in
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Figure: Digital substraction venogram after shunt creation. Tip of catheter is in
main portal vein. Note flow of contrast from portal system into hepatic vein and
inferior vena cava through metallic stent. No filling defect or stenosis is identified.
Table-1: Aetiology of cirrhosis and indications for TIPS.
Total patients: n = 19. Patients with liver cirrhosis: n = 13.
Cause of cirrhosis Number Percentage
Hepatitis C 8 61.54
Hepatitis B 2 15.38
Hepatitis B & C 1 7.69
Alcoholism 1 7.69
Unknown 1 7.69
Indications for TIPS
Indication Number Percentage
Variceal Bleeding 8 42.11
Intractable Ascites 4 21.05
Variceal bleed & Ascites 1 5.26
Budd-Chiari syndrome 6 31.58
84.21% (16 out of 19 patients). 
Major complication rate was 5.26% (Table-2).
Haemoperitoneum in 1 patient was managed by blood
transfusions. Transcapsular puncture of liver occurred in 1
patient with extravasation of contrast in extrahepatic space.
The patient was managed conservatively. Three days
mortality was 15.79 % (n = 3), Two patients died next day of
procedure, 1 of them had multiorgan failure while the other
patient continued to have variceal bleeding and died due to
haemodynamic instability. One patient had a fatal myocardial
infarction and expired after 3 days of the procedure. 
Average follow-up was 312 days. Mean primary shunt
patency was 306.62 days (range 3-1801 days). During
follow-up stent stenosis or occlusion occurred in 31.25 % (n
= 5). 2 patients underwent successful angioplasty while in
other 2 patients shunt patency was satisfactorily restored by
re-stenting. In 1 patient the attempt of re-intervention failed
due to complete thrombosis of the TIPS stent. Multiple
attempts at cannulating this stent were unsuccessful. 
During follow up recurrent bleeding from varices
occurred in 25% patients (n = 4) while recurrence of ascites
occurred in 37.5% patients (n = 6). One patient had
recurrence of both ascites and variceal bleeding.
Discussion
In liver cirrhosis, portal hypertension develops due to
increased sinusoidal and post-sinusoidal resistance to blood
flow. Ascites and porto systemic collaterals occur as a
consequence. Ascites is associated with poor quality of life,
increased risks of infections and a poor long-term outcome.5,6
Bleeding from ruptured esophageal or gastric varices is the
most serious complication of portal hypertension with
mortality rate of approximately 30%. Patients with severe
liver failure have higher mortality.7,8
Idea of mechanical decompression of the portal
system laid the basis of use of portosystemic shunts as a
therapy for portal hypertension. In 1969 Rösch and Hanafee9
described the technique in laboratory animals. The first
human cases were presented by Richter in 1989.10 Since then
the technique is evolving and many reports with variable
numbers of patients, and results have been published. The
procedure has now gained worldwide acceptance. It is
considered an effective and life-saving tool for the
management of complications of portal hypertension.11 As
compared to surgical shunt creation, the procedure is
noninvasive as it avoids the risk of laparotomy, has a
relatively lower frequency of procedure related
complications, and does not preclude future liver
transplantation.7,12
In 1994, the United States National Digestive Diseases
Advisory Board established a set of clinical indications for
TIPS placement.13 These accepted indications are:
 Acute variceal bleeding that cannot be successfully
controlled with medical treatment, including sclerotherapy.
 Recurrent and refractory variceal bleeding or recurrent
variceal bleeding in patients who cannot tolerate
conventional medical treatment, including sclerotherapy and
pharmacologic therapy.
 Therapy for refractory ascites.
Unproven but promising indications include:
 Portal decompression in patients with hepatic venous
outflow obstruction (Budd-Chiari syndrome), hepatic
hydrothorax, or hepatorenal syndrome.
Potential complications of TIPS include transcapsular
puncture and intraperitoneal bleed, haemobilia, sepsis and
shunt infection, hepatic infarction and or encephalopathy and
stent migration.
Although technical refinements have resulted in
reduced morbidity and improved clinical success, the results
of published data are variable. When preformed by trained
interventional radiologists, TIPS is successful in most of the
patients and is generally safe with low procedural
mortality.14-17 Technical failure in 15.78% patients in our
series occurred due to anatomic difficulty and extremely hard
liver parenchyma which prevented acceptable portal venous
puncture.
Shunt malfunction is a major limitation caused by
stenosis or occlusion of the intrahepatic tract either due to
intimal hyperplasia or thrombosis. This impairs the long term
patency of the shunt resulting in recurrence of symptoms.
Primary patency of shunts varies in different series.
Punamiya14 have described primary patency rate at 1, 2, and
3 years is 25-66%, 5-42% and 21% respectively. In the data
presented by Jung et al,18 primary patency rates of uncovered
stents were 63%, 48%, and 24% at 3, 6, and 12 months
respectively. With mean follow up of 306 days, primary stent
patency rate in our series was 68.75% which is comparable to
initial follow up results of Punamiya14 and Jung et al.18
Re-interventions with balloon dilation or stenting to
re-establish or maintain the patency of the shunt are required
in 70%-90% of patients and in 20%-40% total occlusion
develops.19 Stent stenosis or occlusion developed in 31.25%
patients in our study. Patency was restored successfully by
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Table-2: Procedural Complications.
Complications Number Percentage
Total 2 10.53
Major Complication: Haemoperitoneum 1 5.26
Minor complication: Transcapsular puncture of liver 1 5.26
angioplasty or restenting in all patients except one.
TIPS has shown favourable short-term results in
controlling bleeding as compared to endoscopic therapy.
Reported rates of rebleed range from 9% - 22.6%.20-22
Similarly reported efficacy of TIPS in management of
refractory ascites ranges from 63% to 92%.23-25 In our study
group 25% patients had recurrence of variceal bleeding
during follow up. Rate of recurrence of ascites was 37.5%.
High rate of symptom recurrence in our study group is
possibly related to use of uncovered stents in most patients.
Another possible reason is probably related to severity of
liver cirrhosis. Late presentation with advanced cirrhosis in
our belief is the reason for higher symptom recurrence rates.
Availability of new stents covered with
polytetrafluoroethylene (PTFE) membranes has significantly
reduced the rate of TIPS malfunction consequently
improving quality of life and reducing the need for periodic
interventions. 
Conclusion
TIPS is useful for management of complications of
portal hypertension that are refractory to pharmacological
and endoscopic treatment, however shunt stenosis or
occlusion may cause recurrence of symptoms. Repeated
interventions are often required to maintain shunt patency.
Availability of new stents covered with
polytetrafluoroethylene (PTFE) membranes has significantly
reduced the rate of TIPS malfunction consequently
improving quality of life and reducing the need for periodic
interventions.
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